To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […]